In another study, EGFR mutations were associated with better progression-free survival and overall survival, while KRAS mutations were associated with worse survival in NSCLC patients receiving erlotinib, a first-generation tyrosine kinase inhibitor (TKI) [19]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.